Asked by: Blake Stephenson (Conservative - Mid Bedfordshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the press release entitled NHS to invest in pioneering tech to drive down waiting lists, published on 26 September 2025, if he will monitor value for money and return on investment.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is developing Value Based Procurement Standard Guidance to ensure greater consistency in National Health Service procurement and shift decisions towards value and outcomes over unit cost.
13 NHS trusts, covered by nine procurement teams are piloting the guidance prior to its publication and national rollout across the NHS in 2026.
NHS trusts have established governance processes to monitor value for money and return on investment in line with Government policy. The guidance will support NHS procurement teams to do this with information on best practice for setting key performance indicators, baselining, and contract management.
Asked by: Al Pinkerton (Liberal Democrat - Surrey Heath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to raise awareness of the health risks associated with (a) unlicensed or (b) illicit medicines among patients in (i) Surrey and (ii) Surrey Heath constituency.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA), acting on behalf of my Rt Hon. Friend, the Secretary of State for Health and Social Care, is responsible for the regulation of medicines intended for human use in the United Kingdom. This includes applying the legal controls on the retail sale, supply, and advertising of medicines, which are set out in the Human Medicines Regulations 2012.
Sourcing weight loss medicines from unregulated suppliers significantly increases the risk of receiving a product which is either falsified or not authorised for human use. Products purchased in this way will not meet the MHRA’s strict standards for quality, safety, and efficacy and can therefore expose patients to incorrect dosages or dangerous ingredients.
Public safety is the number one priority for the MHRA, and its Criminal Enforcement Unit works hard to prevent, detect, and investigate illegal activity involving medicines and medical devices and takes robust enforcement action where necessary. It works closely with other health regulators, customs authorities, law enforcement agencies, and private sector partners, including e-commerce and the internet industry to identify, remove and block online content promoting the illegal sale of medicines and medical devices.
The MHRA seeks to identify and, where appropriate, prosecute online sellers responsible for putting public health at risk. Between 1 April 2024 and 31 March 2025, the MHRA and its partners seized approximately 17 million doses of illegally traded medicines with a street value of more than £37 million.
During the same period, it disrupted approximately 190,000 website and social media links responsible for advertising medicinal products illegally. Additionally, collaboration with one well-known online marketplace led to the successful identification and blocking of more than 1.5 million unregulated prescription medicines, over-the-counter medicines, and medical devices before they could be offered for sale to the public.
The MHRA is continually developing new and innovative ways to combat the illegal trade in medicines and to raise public awareness. These measures include:
publication of a #Fakemeds campaign which explains how to access medicines through safe and legitimate online sources, with further information available at the following link:
https://fakemeds.campaign.gov.uk/;
public guidance on how to safely access and use GLP-1 medications, available at the following link:
https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know;
development of an online service which allows the public to check if a website has been deemed ‘Not Recommended’ by the MHRA;
development of a web-based reporting scheme allowing the public to report suspicious online sellers to the MHRA; and
extensive work with media outlets to raise awareness of the dangers of illegal medicines.
The MHRA’s continued efforts have led to more medicines being seized than ever before, significant custodial sentences for offenders, the forfeiture of criminal profits and considerable success in disrupting the illegal supply of medicines.
Asked by: Al Pinkerton (Liberal Democrat - Surrey Heath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle the sale and distribution of illicit or unlicensed medicines in (a) Surrey and (b) Surrey Heath constituency.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA), acting on behalf of my Rt Hon. Friend, the Secretary of State for Health and Social Care, is responsible for the regulation of medicines intended for human use in the United Kingdom. This includes applying the legal controls on the retail sale, supply, and advertising of medicines, which are set out in the Human Medicines Regulations 2012.
Sourcing weight loss medicines from unregulated suppliers significantly increases the risk of receiving a product which is either falsified or not authorised for human use. Products purchased in this way will not meet the MHRA’s strict standards for quality, safety, and efficacy and can therefore expose patients to incorrect dosages or dangerous ingredients.
Public safety is the number one priority for the MHRA, and its Criminal Enforcement Unit works hard to prevent, detect, and investigate illegal activity involving medicines and medical devices and takes robust enforcement action where necessary. It works closely with other health regulators, customs authorities, law enforcement agencies, and private sector partners, including e-commerce and the internet industry to identify, remove and block online content promoting the illegal sale of medicines and medical devices.
The MHRA seeks to identify and, where appropriate, prosecute online sellers responsible for putting public health at risk. Between 1 April 2024 and 31 March 2025, the MHRA and its partners seized approximately 17 million doses of illegally traded medicines with a street value of more than £37 million.
During the same period, it disrupted approximately 190,000 website and social media links responsible for advertising medicinal products illegally. Additionally, collaboration with one well-known online marketplace led to the successful identification and blocking of more than 1.5 million unregulated prescription medicines, over-the-counter medicines, and medical devices before they could be offered for sale to the public.
The MHRA is continually developing new and innovative ways to combat the illegal trade in medicines and to raise public awareness. These measures include:
publication of a #Fakemeds campaign which explains how to access medicines through safe and legitimate online sources, with further information available at the following link:
https://fakemeds.campaign.gov.uk/;
public guidance on how to safely access and use GLP-1 medications, available at the following link:
https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know;
development of an online service which allows the public to check if a website has been deemed ‘Not Recommended’ by the MHRA;
development of a web-based reporting scheme allowing the public to report suspicious online sellers to the MHRA; and
extensive work with media outlets to raise awareness of the dangers of illegal medicines.
The MHRA’s continued efforts have led to more medicines being seized than ever before, significant custodial sentences for offenders, the forfeiture of criminal profits and considerable success in disrupting the illegal supply of medicines.
Asked by: Tom Hayes (Labour - Bournemouth East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if his Department will review the Mental Health Act 1983 to ensure people with co-occurring mental health and substance misuse needs are not excluded from treatment.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Mental Health Act 2025 will give patients greater choice, enhanced rights and support, and ensure everyone is treated with dignity and respect throughout treatment.
We know that people with co-occurring substance use and mental health needs do not always receive the integrated, person-centred care they require and deserve. We are committed to promoting more cohesion between mental health services and substance use services, to ensure people, included those subject to the Mental Health Act, no longer fall through the gaps of treatment. The Department and NHS England have published the Co-occurring Mental Health and Substance Use Delivery framework, which provides national commitments and calls to the sector on how the health system can improve delivery of integrated, person-centred care across drug and alcohol treatment and mental health services.
In developing this plan, we have worked with subject matter experts, including people with lived experience, academics, clinicians, and service providers, to set out a path to improving service provision for those with co-occurring substance use and mental health needs. This standard provides guidance for drug and alcohol treatment commissioners on improving services for people with co-occurring mental health and alcohol or drug conditions and how local services need to work together so that people can access the help they need.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of NHS spending on pharmaceutical products on levels of NHS staffing, equipment and activity in the context of the UK-US trade deal.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Every patient deserves access to the best possible treatment. By increasing the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold, we are increasing the value that we place on innovations that deliver improvements to patient health. Alongside the changes that we announced in the Life Sciences Sector Plan this will increase both the speed and breadth of patient access to innovative medicines and encourage growth in United Kingdom based clinical trials. This is supported by confirmation that, thanks to strong UK support for innovation, the UK has secured mitigations under the United States of America’s ‘Most Favoured Nation’ drug pricing initiative.
This deal will also benefit our life sciences sector, driving jobs, investment, and growth. We have secured a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the UK’s medical technology exports, meaning no additional new tariffs on medical technology.
The move has secured the confidence of the pharmaceutical industry that the UK is a top destination for investment and growth, with major firms like Moderna, Prologis, and BioNTech investing billions here, and renewed confidence in the UK.
Costs will start smaller but will increase over time as NICE approves more life improving and lifesaving medicines. Total costs over the spending review period are expected to be approximately £1 billion. But the final costs will depend on which medicines NICE decides to approve and the actual uptake of these.
Asked by: Blake Stephenson (Conservative - Mid Bedfordshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the answer of 24 October 2025 to Written Question 75761, what criteria he uses to determine cost-effectiveness.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The criteria used to determine the cost-effectiveness of offering services in the NHS App is yet to be finalised, as scoping is at an early stage and will take place alongside the business planning process for the Spending Review period.
Asked by: Martin Vickers (Conservative - Brigg and Immingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of adopting a preventative approach to mental health; and what steps he is taking to support such an approach.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government’s 10-Year Health Plan sets out ambitious plans to transform mental health services. We want to promote good mental health and wellbeing for the nation, prevent people from developing mental health problems, and improve the lives of people living with a mental health condition. This includes providing mental health support teams in schools and colleges, improving assertive outreach, investing in mental health emergency departments, and increasing access to evidence-based digital interventions.
Additionally, the Office for Health Improvement and Disparities Regional Public Health team work closely with local councils to become signatories to the Prevention Concordat for Better Mental Health. This includes developing local plans to improve mental wellbeing across the life course and to reduce inequalities in mental health, working with partners across the health and care system, as well as schools and employers.
The Government has also recently launched an independent review into prevalence and support for mental health conditions, attention deficit hyperactivity disorder, and autism. This review will seek to identify opportunities to provide different models of support and pathways, within and beyond the National Health Service, that promote prevention and early intervention.
Asked by: Blake Stephenson (Conservative - Mid Bedfordshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the adequacy of safeguards in AI when dealing with mental health based queries.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department recognises the importance of safeguards when using artificial intelligence (AI) for mental health queries. The United Kingdom has a world-leading regulatory system, and the National Health Service operates within a comprehensive regulatory framework for AI, underpinned by rigorous standards established by bodies including the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, the Health Research Authority, and the Care Quality Commission. These agencies ensure that AI technologies are safe, effective, and ethically deployed within healthcare settings.
Publicly available AI applications that are not deployed by the NHS, such as ChatGPT or Google’s Gemini, are not regulated as medical technologies and may offer incorrect or harmful information. Users are strongly advised to be careful when using these technologies. The Department recommends that individuals seek advice from the NHS website, which provides clinically approved guidance on mental health-based queries, or that they reach out to healthcare professionals.
The Department continues to work with NHS England and regulators to strengthen oversight and ensure AI in health and care is safe, effective, and accountable.
Asked by: Blake Stephenson (Conservative - Mid Bedfordshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the answer of 8 October 2025 to written question 75742, if he will make an estimate of the resources required for continuous monitoring.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Detailed planning is still underway for the Spending Review period, which would include the continuous monitoring of all elements of the NHS App, including artificial intelligence assisted triage functionality. At this stage no estimate has been made of the resources required for the continuous monitoring of the triage functions of the NHS App specifically, but it is being included and is a key element when considering how to deliver this change.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of NHS spending on pharmaceutical products on the economy in the context of the UK-US trade deal.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Every patient deserves access to the best possible treatment. By increasing the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold, we are increasing the value that we place on innovations that deliver improvements to patient health. Alongside the changes that we announced in the Life Sciences Sector Plan this will increase both the speed and breadth of patient access to innovative medicines and encourage growth in United Kingdom based clinical trials. This is supported by confirmation that, thanks to strong UK support for innovation, the UK has secured mitigations under the United States of America’s ‘Most Favoured Nation’ drug pricing initiative.
This deal will also benefit our life sciences sector, driving jobs, investment, and growth. We have secured a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the UK’s medical technology exports, meaning no additional new tariffs on medical technology.
The move has secured the confidence of the pharmaceutical industry that the UK is a top destination for investment and growth, with major firms like Moderna, Prologis, and BioNTech investing billions here, and renewed confidence in the UK.
Costs will start smaller but will increase over time as NICE approves more life improving and lifesaving medicines. Total costs over the spending review period are expected to be approximately £1 billion. But the final costs will depend on which medicines NICE decides to approve and the actual uptake of these.